Overview

Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma

Status:
Recruiting
Trial end date:
2026-09-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether pembrolizumab given after standard ablative Radiotherapy is a safe treatment that causes few or mild side effects in people with advanced Adrenocortical Carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Treatments:
Pembrolizumab